Trial Profile
Phase II Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2018
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 16 Dec 2009 New trial record